(Q54411332)

29 May 2018

title

Probiotic E. coli treatment mediates antimicrobial human beta-defensin synthesis and fecal excretion in humans. (English)

1 reference

29 May 2018

0 references

0 references

1 reference

9

1 reference

29 May 2018

author name string

M Möndel

1

1 reference

29 May 2018

B O Schroeder

2

1 reference

29 May 2018

K Zimmermann

3

1 reference

29 May 2018

H Huber

4

1 reference

29 May 2018

S Nuding

5

1 reference

29 May 2018

J Beisner

6

1 reference

29 May 2018

K Fellermann

7

1 reference

29 May 2018

E F Stange

8

1 reference

29 May 2018

publication date

26 November 2008

1 reference

29 May 2018

published in

Mucosal Immunology

1 reference

29 May 2018

volume

2

1 reference

29 May 2018

issue

2

1 reference

29 May 2018

page(s)

166-172

1 reference

29 May 2018

Probiotics: an overview of beneficial effects.

cites work

1 reference

https://api.crossref.org/works/10.1038%2FMI.2008.77

7 January 2021

Clinical applications of probiotic agents

1 reference

https://api.crossref.org/works/10.1038%2FMI.2008.77

7 January 2021

Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhoea and shedding of rotavirus

1 reference

https://api.crossref.org/works/10.1038%2FMI.2008.77

7 January 2021

The probiotic Escherichia coli strain Nissle 1917 (EcN) stops acute diarrhoea in infants and toddlers

1 reference

https://api.crossref.org/works/10.1038%2FMI.2008.77

7 January 2021

Protection from gastrointestinal diseases with the use of probiotics

1 reference

https://api.crossref.org/works/10.1038%2FMI.2008.77

7 January 2021

Intestinal microflora in human and experimental inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038%2FMI.2008.77

7 January 2021

Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum

1 reference

https://api.crossref.org/works/10.1038%2FMI.2008.77

7 January 2021

Inflammatory Bowel Disease

1 reference

https://api.crossref.org/works/10.1038%2FMI.2008.77

7 January 2021

Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1038%2FMI.2008.77

7 January 2021

Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine

1 reference

https://api.crossref.org/works/10.1038%2FMI.2008.77

7 January 2021

Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FMI.2008.77

7 January 2021

Probiotics--role in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038%2FMI.2008.77

7 January 2021

Defensins and other antimicrobial peptides in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038%2FMI.2008.77

7 January 2021

NF-kappaB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium.

1 reference

https://api.crossref.org/works/10.1038%2FMI.2008.77

7 January 2021

Epithelial antimicrobial peptides: innate local host response elements

1 reference

https://api.crossref.org/works/10.1038%2FMI.2008.77

7 January 2021

Antimicrobial peptides as mediators of epithelial host defense

1 reference

https://api.crossref.org/works/10.1038%2FMI.2008.77

7 January 2021

Probiotic lactobacilli and VSL#3 induce enterocyte beta-defensin 2.

1 reference

https://api.crossref.org/works/10.1038%2FMI.2008.77

7 January 2021

Induction of human beta-defensin 2 by the probiotic Escherichia coli Nissle 1917 is mediated through flagellin.

1 reference

https://api.crossref.org/works/10.1038%2FMI.2008.77

7 January 2021

Secreted enteric antimicrobial activity localises to the mucus surface layer.

1 reference

https://api.crossref.org/works/10.1038%2FMI.2008.77

7 January 2021

Reduced Paneth cell alpha-defensins in ileal Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FMI.2008.77

7 January 2021

Activated innate immune system in irritable bowel syndrome?

1 reference

https://api.crossref.org/works/10.1038%2FMI.2008.77

7 January 2021

Ultrasensitive assays for endogenous antimicrobial polypeptides

1 reference

https://api.crossref.org/works/10.1038%2FMI.2008.77

7 January 2021

Identifiers

DOI

10.1038/MI.2008.77

1 reference

29 May 2018

Dimensions Publication ID

1009825489

0 references

1 reference

29 May 2018